Society for Neuroscience Annual Meeting 2013

CONFERENCE COVERAGE SERIES Researchers Revel in C9ORF72 Advances at RNA Symposium Profilin-1 Links Cytoskeleton and RNA Aggregation in ALS The Four Stages of TDP-43 Proteinopathy Blocking a MicroRNA Slows Motor Neuron Disease in Mice Glial Cells Refine Neural Circuits Innate Immune

BACE1

ALZPEDIA BACE1 encodes a transmembrane aspartyl protease responsible for β-secretase processing of the amyloid precursor protein (APP). APP cleavage by BACE1 is the rate-limiting step in the generation of Aβ peptides, creating the C99 fragment that becomes a subst

Clinical Trials on Alzheimer's Disease 2011

CONFERENCE 2011-11-03 00:00:00-2011-11-05 00:00:00 San Diego, CA, U.S.A. 03 November 2011 to 05 November 2011 Clinical Trials on Alzheimer's Disease 2011 View Conference Website 0

Clinical Trials on Alzheimer's Disease 2010

CONFERENCE 2010-11-03 00:00:00-2010-11-05 00:00:00 Toulouse, France 03 November 2010 to 05 November 2010 Clinical Trials on Alzheimer's Disease 2010 View Conference Website 0

ADAM10

ALZPEDIA ADAM10 stands for A Disintegrin and Metalloproteinase 10. This membrane protein is a sheddase and thought to be the physiological α-secretase for the amyloid precursor protein (APP). In contrast to cleavage by β-secretase, ADAM10-mediated processing of AP

The Dementia Challenge: Responding to a National Priority

CONFERENCE 2014-04-08 00:00:00-2014-04-08 00:00:00 The Mermaid Conference & Events Centre, London, England, U.K. 08 April 2014 This inaugural conference will present an array of high profile, expert speakers to deliver a clear understanding into the current situation and planned future developments. T

PAPER Tagliavini F, Rossi G, Padovani A, Magoni M, Andora G, Sgarzi M, Bizzi A, Savoiardo M, Carella F, Morbin M, Giaccone G, Bugiani O

A new βPP mutation related to hereditary cerebral haemorrhage

Alzheimer's Reports. 1999; 2(S1):S28.

G8 Dementia Summit

CONFERENCE 2013-12-11 00:00:00-2013-12-11 00:00:00 London, England 11 December 2013 0

Sheila Chervin

N/A
Larchmont, United States

PAPER Hunter C, Jankovic J

Double-blind, placebo-controlled study to assess safety and efficacy of riluzole as a neuroprotective drug in patients with early, untreated Parkinson's disease.

Neurology. 52 (Suppl. 2): 214-215, 12 Apr 1999. USA

PAPER Cudkowicz, Rosas, Hayden

Riluzole therapy in patients with Huntington's disease.

Neurology. 50 (Suppl. 4): 72, Apr 1998

A Sahal on ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease.

COMMENT I recommend this paper. 0 Arwa.o

Steven Paul on Averting a Late-life Crisis: Midlife ApoE2 Clears Plaques in Mice

COMMENT The paper by Hudry et al. is a beautiful extension of a paper my lab published almost nine years ago using viral vectors to deliver ApoE isoforms to the brains of PDAPP mice (see Dodart et al., 2005). In our study we showed that direct intrahippocampal ad

Paul Coleman on More Evidence for AD Starting Without Brain Amyloid

COMMENT I suggest that the E693delta (Osaka) mutation in APP may be pertinent to the SNAP cases (e.g., Tomiyama et al., 2008; Shimada et al., 2011). Paul_Coleman 0 A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Clinical cou

Takaomi Saido on The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.

COMMENT To my knowledge, this is the first paper describing neuropathology of AD patients with Arctic mutation. 0 saido